Quality assessment of common anti-malarial medicines marketed in Gambella, National Regional State, South Western-Ethiopia.
Antimalarials
Ethiopia
Gambella
Malaria
Poor quality
Quality assessment
Substandard and falsified (SF) medicines
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
13 Sep 2024
13 Sep 2024
Historique:
received:
06
03
2024
accepted:
22
08
2024
medline:
14
9
2024
pubmed:
14
9
2024
entrez:
13
9
2024
Statut:
epublish
Résumé
Over the past years, there has been a growing concern that a considerable amount of anti-malarial supply in the underdeveloped world particularly in the private sector, is of poor quality. The World Health Organization (WHO) has received about 1500 reports that mentions instances of substandard and falsified products since 2013. The majority of the reports concerned antibiotics and anti-malarials. The majority of reports (42%) originate from the WHO African region. This study intends to assess the quality of the most widely used anti-malarial medications [artemether-lumefantrine tablets, chloroquine phosphate tablets, primaquine phosphate tablets, artesunate, and artemether injections] in Gambella, South-West, Ethiopia. A total of 52 samples were collected on June 2022 from Gambella National Regional State, Ethiopia. Half of the districts (six) located in the four zones of the region were chosen using simple random sampling technique. All drug retail outlets available in the selected districts (locally known as woredas) were included. The samples were subjected to visual inspection with a tool adopted from the joint WHO/FIP/ USP checklist. The pharmacopeial tests for identification, uniformity of dosage forms, assay, thickness, diameter, hardness, friability, disintegration test, dissolution, and sterility tests were carried out according to the USP 44-NF 39 and International Pharmacopoeia 11th edition, 2022 monographs. Only 25% of the samples were registered on the Ethiopian Food and Drug Authority (EFDA's) electronic regulatory/ registration system (ERIS). Besides, 88.8% of artemether injection products were presented in clear glass ampoules. This might expose the products to photochemical degradation that leads to in loss of anti-plasmodial activity. In addition, 50% of the artemether products assessed were not bioequivalent with the comparator product in the in vitro dissolution comparison tests. Overall, the study findings reveal a high prevalence (58.3%) of substandard anti-malarial drugs in the region. The stated percent of the samples had failed in one or more of the quality test parameters assessed in this study. The study findings reveal a high prevalence (58.3%) of substandard anti-malarial drugs in the region. Only a quarter were registered and 38% of the unregistered products failed the quality tests. Hence, the national, regional medicine regulatory bodies and other stake holders should perform the required roles to circumvent presence of Substandard and Falsified (SF) anti-malarial drugs in the study sites.
Sections du résumé
BACKGROUND
BACKGROUND
Over the past years, there has been a growing concern that a considerable amount of anti-malarial supply in the underdeveloped world particularly in the private sector, is of poor quality. The World Health Organization (WHO) has received about 1500 reports that mentions instances of substandard and falsified products since 2013. The majority of the reports concerned antibiotics and anti-malarials. The majority of reports (42%) originate from the WHO African region.
OBJECTIVE
OBJECTIVE
This study intends to assess the quality of the most widely used anti-malarial medications [artemether-lumefantrine tablets, chloroquine phosphate tablets, primaquine phosphate tablets, artesunate, and artemether injections] in Gambella, South-West, Ethiopia.
METHODS
METHODS
A total of 52 samples were collected on June 2022 from Gambella National Regional State, Ethiopia. Half of the districts (six) located in the four zones of the region were chosen using simple random sampling technique. All drug retail outlets available in the selected districts (locally known as woredas) were included. The samples were subjected to visual inspection with a tool adopted from the joint WHO/FIP/ USP checklist. The pharmacopeial tests for identification, uniformity of dosage forms, assay, thickness, diameter, hardness, friability, disintegration test, dissolution, and sterility tests were carried out according to the USP 44-NF 39 and International Pharmacopoeia 11th edition, 2022 monographs.
RESULTS AND DISCUSSION
CONCLUSIONS
Only 25% of the samples were registered on the Ethiopian Food and Drug Authority (EFDA's) electronic regulatory/ registration system (ERIS). Besides, 88.8% of artemether injection products were presented in clear glass ampoules. This might expose the products to photochemical degradation that leads to in loss of anti-plasmodial activity. In addition, 50% of the artemether products assessed were not bioequivalent with the comparator product in the in vitro dissolution comparison tests. Overall, the study findings reveal a high prevalence (58.3%) of substandard anti-malarial drugs in the region. The stated percent of the samples had failed in one or more of the quality test parameters assessed in this study.
CONCLUSION
CONCLUSIONS
The study findings reveal a high prevalence (58.3%) of substandard anti-malarial drugs in the region. Only a quarter were registered and 38% of the unregistered products failed the quality tests. Hence, the national, regional medicine regulatory bodies and other stake holders should perform the required roles to circumvent presence of Substandard and Falsified (SF) anti-malarial drugs in the study sites.
Identifiants
pubmed: 39272079
doi: 10.1186/s12936-024-05091-x
pii: 10.1186/s12936-024-05091-x
doi:
Substances chimiques
Antimalarials
0
Artemether, Lumefantrine Drug Combination
0
Substandard Drugs
0
Counterfeit Drugs
0
Artesunate
60W3249T9M
Chloroquine
886U3H6UFF
Primaquine
MVR3634GX1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
278Informations de copyright
© 2024. The Author(s).
Références
Dembele O. Risk-based post-marketing surveillance (RB-PMS2) of antimalarial and MNCH drugs in Mali (PY2). Int J Pharm Bio-Med Sci. 2022;2:09.
doi: 10.47191/ijpbms/v2-i9-06
WHO. World malaria report 2020: 20 years of global progress and challenges. [Internet]. Geneva, World Health Organization, 2020. https://apps.who.int/iris/handle/10665/337660 . (Accessed: 6 September 2022).
WHO. World malaria report 2022. . [Internet]. Geneva, World Health Organization, 2022. https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report . [Accessed 29 May 2023].
Walker EJ, Peterson GM, Grech J, Paragalli E, Thomas J. Are we doing enough to prevent poor-quality antimalarial medicines in the developing world? BMC Public Health. 2018;18:630.
doi: 10.1186/s12889-018-5521-7
pubmed: 29764407
pmcid: 5952616
Al-Worafi YM. Counterfeit and substandard medications drug safety in `developing countries: achievements and challenges. London: Elsevier; 2020.
Lalani M, Kaur H, Mohammed N, Mailk N, van Wyk A, Sakhi J, et al. Substandard antimalarials available in Nigerian: a case for assessing the quality of drugs in resource poor settings. Am J Trop Med Hyg. 2015;92(Suppl 6):51–8.
doi: 10.4269/ajtmh.14-0394
pubmed: 25897070
pmcid: 4455088
WHO. Survey of the quality of selected antimalarial medicines circulating in six countries of sub-Saharan Africa. Geneva, World Health Organization, 2011. https://www.afro.who.int/publications/survey-quality-selected-antimalarial-medicines - circulating-six-countries-sub-saharan [Accessed 24 Jan. 2023].
FMOH. National Malaria guideline 4
Dillu D, Reda HL, Tesfaye G. Malaria Elimination Roadmap in Ethiopia. Federal Democratic Republic of Ethiopia, MOH, Addis Ababa, 2017. Available from: https://www.researchgate.net/publication/342889504_Malaria_Elimination_Roadmap_in_Ethiopia . [Accessed 2 October 2022]
Ethiopian Demography and Health. Gambella. 2014. https://www.ethiodemographyandhealth.org/Gambella.html . [Accessed 7 Oct. 2022].
Central Statistical Agency. Central Statistical Agency (CSA) Population projection of Ethiopia for all regions at wereda level from 2014–2017. Addis Ababa. –References–Scientific Research Publishing. 2018. https://www.scirp.org/(S(351jmbntvnsjt1aadkposzje))/reference/referencespapers.aspx?r eferenceid=2486024. [Accessed 25 Feb. 2023].
UNHCR Global Report. UNHCR Operational Data Portal (ODP). 2021. https://data.unhcr.org/en/documents/details/93861 . [Accessed 27 May, 2023]
The International Pharmacopoeia. Digicollections.net. 2020. https://digicollections.net/phint/2022/index.html#p/home . [Accessed January 2 2023]
United States Pharmacopeia. US Pharmacopoeia National Formulary, USP 44/NF39, United States Pharmacopoeial Convention. Rockville, MD.
United States Pharmacopeia. Uniformity of Dosage Units. In: USP-NF 44/39. US Pharmacopeia convention. Rockville, MD: United States Pharmacopeia.
International Pharmacopoeia. Digicollections.net. 2022. https://digicollections.net/phint/2022/index.html#p/home . (Accessed Jan 2023)
United States Pharmacopoeia. (2023). General Chapter, <1216>Tablet Friability. In: USP-NF44/39. Rockville, MD: United States Pharmacopoeia.
British Pharmacopoeia. (2000). London Stationary Office. Her Majesty’s Stationary Office.
United States Pharmacopeia USP Monographs, Chloroquine Phosphate Tablets In: USP-NF.44/39 US Pharmacopeia convention. Rockville, USA.
Australian Government Department of Health and Aged Care. Comparative dissolution profiles for biopharmaceutic studies. 2019. https://www.tga.gov.au/resources/resource/guidance/biopharmaceutic-studies/152-comparative-dissolution-profiles-biopharmaceutic-studies . [Accessed 15 May 2023].
Nogueira FHA, Moreira-Campos LM, dos Santos RLC, Pianetti GA. Quality of essential drugs in tropical countries: evaluation of antimalarial drugs in the Brazilian Health System. Rev Soc Brasil Med Trop. 2011;2011(44):582–6.
doi: 10.1590/S0037-86822011000500010
Abuye H, Abraham W, Kebede S, Tatiparthi R, Suleman S. Physicochemical quality assessment of antimalarial medicines: chloroquine phosphate and quinine sulfate tablets from drug retail outlets of South-West Ethiopia. Infect Drug Resist. 2020;13:691–701.
doi: 10.2147/IDR.S234684
pubmed: 32161477
pmcid: 7051250
U.S. President’s Malaria Initiative. Countering unregistered and illegal antimalarial drugs in Ethiopia. PMI. 2013. https://www.pmi.gov/countering-unregistered-and-illegal-antimalarial-drugs-in-ethiopia/ . [Accessed 12 Feb. 2023].
WHO. Substandard and falsified medical products. 2017. https://www.who.int/news-room/fact-sheets/detail/substandard%20and-falsifed-medical - products. [Accessed 10 Mar. 2023].
Sutherland A, Waldek S. It is time to review how unlicensed medicines are used. Eur J Clin Pharmacol. 2015;71:1029–35.
doi: 10.1007/s00228-015-1886-z
pubmed: 26153083
pmcid: 4532700
Ndomondo-Sigonda M, Miot J, Naidoo S, Dodoo A, Kaale E. Medicines regulation in Africa: current state and opportunities. Pharmaceut Med. 2017;31:383–97.
pubmed: 29200865
pmcid: 5691122
Hassan IA, Adegbola AJ, Soyinka JO, Onyeji CO, Bolaji O. Post- marketing surveillance of quality of artemether injection marketed in Southwest Nigeria. Am J Trop Med Hyg. 2020;103:1258–65.
doi: 10.4269/ajtmh.20-0190
pubmed: 32588802
pmcid: 7470523
Angeli DG, Trezza C. Quality and stability of ramipril generics/copies versus reference ramipril (Tritace®). Clin Drug Investig. 2009;29:667–76.
doi: 10.2165/11315270-000000000-00000
pubmed: 19715383
Belew S, Suleman S, Mohammed T, Mekonnen Y, Duguma M, Teshome H, et al. Quality of fixed dose artemether/lumefantrine products in Jimma Zone. Ethiopia Malar J. 2019;18:236.
doi: 10.1186/s12936-019-2872-1
pubmed: 31307475
Visser BJ, Meerveld-Gerrits J, Kroon D, Mougoula J, Vingerling R, Bache E, et al. Assessing the quality of anti-malarial drugs from Gabonese pharmacies using the MiniLab®: a field study. Malar J. 2015;14:273.
doi: 10.1186/s12936-015-0795-z
pubmed: 26169915
pmcid: 4501108
Chaccour CJ, Kaur H, Mabey D, Del Pozo JL. Travel and fake artesunate: a risky business. Lancet. 2012;380:1120.
doi: 10.1016/S0140-6736(12)60649-7
pubmed: 22998721
Prah J, Ameyaw EO, Afoakwah R, Fiawoyife P, Oppong-Danquah E, Boampong JN. Quality assessment of artemether-lumefantrine samples and artemether injections sold in the Cape Coast Metropolis. J Trop Med. 2016;2016:8602619.
doi: 10.1155/2016/8602619
pubmed: 27006665
pmcid: 4781956
U.S. Food and Drug Administration. Allowable excess volume and labeled vial fill size in injectable drug and biological products. Final Guidance Document, 2015. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/allowable-excess-volume-and-labeled-vial-fill-size-injectable-drug-and-biological-products . [Accessed Feb 20, 2023]
Ouji M, Augereau J-M, Paloque L, Benoit-Vical F. Plasmodium falciparum resistance to artemisinin-based combination therapies: a sword of Damocles in the path toward malaria elimination. Parasite. 2018;25:24.
doi: 10.1051/parasite/2018021
pubmed: 29676250
pmcid: 5909375
Uzondu E, Okafo E. Comparative assessment of the quality of some commercial brands of artesunate and amodiaquine antimalarial combination drugs in the Nigerian market. World J Pharmaceut Res. 2016;5:275–91.
Mufusama J-P, Ndjoko Ioset K, Feineis D, Hoellein L, Holzgrabe U, Bringmann G. Quality of the antimalarial medicine artemether – lumefantrine in 8 cities of the Democratic Republic of the Congo. Drug Test Anal. 2018;10:1599–606.
doi: 10.1002/dta.2420
pubmed: 29896850
The International Pharmacopoeia. Digicollections.net. 2019. [Accessed 25 Jan 2023]
Risha PG, Shewiyo D, Msami A, Masuki G, Vergote G, Vervaet C, et al. In vitro evaluation of the quality of essential drugs on the Tanzanian market. Trop Med Int Health. 2002;7:701–7.
doi: 10.1046/j.1365-3156.2002.00937.x
pubmed: 12167097
Kaur H, Allan EL, Mamadu I, Hall Z, Ibe O, El Sherbiny M, et al. Quality of artemisinin-based combination formulations for malaria treatment: prevalence and risk factors for poor quality medicines in public facilities and private sector drug outlets in Enugu. Nigeria PLoS One. 2015;10: e0125577.
doi: 10.1371/journal.pone.0125577
pubmed: 26018221
United States Pharmacopeia. Tablet Breaking Force USP- NF 44/39. USA: US Pharmacopeia Convention. Rockville; 2022.
Center for Drug Evaluation and Research. About FDA Guidances. U.S. Food and Drug Administration. 2019. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm . [Accessed 24 Feb. 2023].
Akinleye M, Adelaja I, Odulaja J. Comparative evaluation of physicochemical properties of some commercially available brands of Metformin HCl tablets in Lagos, Nigeria. 2012. https://www.semanticscholar.org/paper/Comparative - Evaluation-of-Physicochemical-of-Some-Akinleye- Adelaja/1248d4e7139a9a0a4c733cb743ce4f223d7393b3 [Accessed 25 Feb. 2023].
Girma M, Umeta B, Hasen G, Suleman S. Quality of antimalarial drugs in East Africa: a systematic review. Infect Drug Resist. 2022;15:6085–92.
doi: 10.2147/IDR.S373059
pubmed: 36277242
pmcid: 9585264
Patel AK, Prajapati BG, Moria RS, Patel CN. In-vitro evaluation of marketed antimalarial chloroquine phosphate tablets. J Vector Borne Dis. 2005;42:147–50.
pubmed: 16457384
Gwaziwa NN, Mupa M, Dzomba P. A quality control study of ibuprofen tablets available in the formal and informal market in Harare. Zimbabwe Afr J Pharm Pharmacol. 2017;11:195–203.
Shah V. Dissolution: a quality control test vs a bioequivalent test. Dissolution Technol. 2001;8:1–2.
doi: 10.14227/DT080401P6
Hassali MA, Thambyappa J, Hisham A, Saleem Ul Haq F, Aljadhey N. Generic substitution in Malaysia: recommendations from a systematic review. J Appl Pharmaceut Sci. 2012;2(159):64.
Alburyhi M, Alwan M, Aboghanem AA. Effect of different excipients on formulation of immediate release artemether/lumefantrine tablets. J Chem Pharmaceut Res. 2013;5:617–25.
Saville DJ. Influence of storage on in-vitro release of ibuprofen from sugar coated tablets. Intl J Pharmaceut. 2001;224:39–49.
doi: 10.1016/S0378-5173(01)00734-7